New drug combo shows promise for tough cancers
NCT ID NCT05544929
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 25 times
Summary
This early-stage study tests a new drug called KFA115, alone or with pembrolizumab, in people with advanced cancers like lung, skin, kidney, and others. The main goal is to find the safest dose and understand side effects. About 126 participants will be enrolled to see if the treatment can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Massachusetts General Hospital .
Boston, Massachusetts, 02114, United States
-
NYU School of Medicine
New York, New York, 10015, United States
-
Novartis Investigative Site
Toronto, Ontario, M5G 2M9, Canada
-
Novartis Investigative Site
Guangzhou, Guangdong, 510080, China
-
Novartis Investigative Site
Beijing, 100036, China
-
Novartis Investigative Site
Lyon, 69373, France
-
Novartis Investigative Site
Dresden, Saxony, 01307, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Hong Kong, 999077, Hong Kong
-
Novartis Investigative Site
Milan, MI, 20133, Italy
-
Novartis Investigative Site
Modena, MO, 41124, Italy
-
Novartis Investigative Site
Chuo Ku, Tokyo, 104 0045, Japan
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.